Somatostatinoma

Amir Hamrahian, M.D., Reshmi Srinath, M.D.
Somatostatinoma is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

DEFINITION

  • Rare neuroendocrine tumors (NETs) that arise primarily in the pancreas (from D cells) and duodenum.
  • May or may not secrete excess somatostatin, called somatostatinoma syndrome.
  • Somatostatin inhibits the secretion of endocrine hormones including insulin which contributes to development of diabetes as well as paracrine hormones including cholecystokinin, vasoactive intestinal peptide (VIP), gastric inhibitory polypeptide (GIP), and pancreatic polypeptide (PP).[17]

-- To view the remaining sections of this topic, please or --

DEFINITION

  • Rare neuroendocrine tumors (NETs) that arise primarily in the pancreas (from D cells) and duodenum.
  • May or may not secrete excess somatostatin, called somatostatinoma syndrome.
  • Somatostatin inhibits the secretion of endocrine hormones including insulin which contributes to development of diabetes as well as paracrine hormones including cholecystokinin, vasoactive intestinal peptide (VIP), gastric inhibitory polypeptide (GIP), and pancreatic polypeptide (PP).[17]

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: June 9, 2020